5 Topic Commentaries

A Comprehensive Review of Monoclonal Gammopathy of Undetermined Significance

• 

  S. Vincent Rajkumar, M.D.

  Hematology/Oncology

  •

  Mayo Clinic

  Monoclonal gammopathy of undetermined significance is present in more than 3 percent of the general population age 50 and older.

  Source
• 

  C. Ola Landgren, MD, PhD

  Hematology/Oncology (Multiple Myeloma)

  •

  Memorial Sloan Kettering Cancer Center

  The clinical guidelines for multiple myeloma don’t currently address being tested for MGUS.

  Source
• 

  Matthew T. Drake, M.D., Ph.D.

  Endocrinology (Bone Health)

  •

  Mayo Clinic

  Together, these findings may provide insight into the increased fracture incidence seen in MGUS.

  Source
• 

  Urvi Shah, MD

  Hematology/Oncology

  •

  Memorial Sloan Kettering Cancer Center

  This is the first study of its kind to show that a high-fiber plant-based intervention may delay progression from MGUS or SMM to multiple myeloma.

  Source
• 

  Joselle Cook, M.B.B.S.

  Hematology/Oncology

  •

  Mayo Clinic

  If we detect M-protein in a person's blood, and we aren't concerned about organ damage, we monitor them.

  Source